FDA’s Congressional Relations, Internal Structure May Change With Sharfstein’s Departure
The departure of Principal Deputy Commissioner Joshua Sharfstein provides FDA an opportunity to take stock of its relationship with the new Congress and to re-evaluate its own organizational structure.
You may also be interested in...
Rachel Sherman takes over a position that has not been filled permanently since Josh Sharfstein left in 2011.
Former FDA Principal Deputy Commissioner Joshua Sharfstein suggests FDA create a pathway for development of new products for simultaneous treatment of chronic pain and opioid disorder.
John Taylor’s exit from the agency comes as FDA Commissioner Margaret Hamburg awaits recommendations from a panel of senior agency officials on how to ensure the centers support Office of Regulatory Affairs’ activities without duplication.